BioPharmSignal logoBioPharmSignal

Biotech News

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MannKind (MNKD)MannKindEarnings

Conference call today at 9:00 am ET Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix ® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza ® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues of $349M, +22% vs. 2024 Successfully completed the acquisition of

Open original release

Related news

MNKDMannKind2026-02-18 14:00 EST

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

MNKDMannKind2026-05-06 20:01 EST

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

VANIVivani Medical2026-03-26 20:16 EST

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MISTMilestone Pharmaceuticals Inc.2026-03-20 11:55 EST

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

MISTMilestone Pharmaceuticals Inc.2026-03-12 12:00 EST

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

MLYSMineralys Therapeutics2026-03-09 12:00 EST

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

ALGSAligos Therapeutics2026-03-05 13:00 EST

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

CVRXCVRx2026-02-12 21:05 EST

CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

EMBCEmbecta2025-11-25 11:30 EST

Embecta Corp. Reports Fiscal 2025 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2026 Financial Guidance

SYBXSynlogic2024-03-19 11:00 EST

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

View all latest news

MannKind

MannKind is a specialty pharmaceutical company best known for Afrezza and inhaled therapeutic delivery. The company has worked to build a broader inhaled-platform story around respiratory and diabetes care.

Recent company news

MNKDMannKind2026-06-03 10:05 EST

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

MNKDMannKind2026-05-29 18:00 EST

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

MNKDMannKind2026-05-29 16:30 EST

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

MNKDMannKind2026-05-27 20:00 EST

MannKind to Present at Jefferies Global Healthcare Conference

MNKDMannKind2026-05-27 13:05 EST

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

Stock data

Close
3.95 USD
Market cap
1.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States